Abstract: In a process of varying pressure of a pressure container (24) accommodating a forearm (22) of a subject (20) in a pressure range including negative pressure, a diameter (cross-sectional shape value) (D) of an artery 44 in the forearm (22) accommodated in the pressure container (24) is measured non-invasively by a vascular diameter calculating unit (76). In addition, a display controller (display controlling means) (80) operates to display on a displaying device (16) a variation of an internal pressure (Pc) in the pressure container (24) and a variation of the diameter (D) of the artery (44) varying depending thereon. Based on the diameter (D) of the artery (44) obtained in the high pressure region, the variation of the internal pressure Pc in the pressure container 24 and the variation of the diameter (D) of the artery 44 varying depending thereon i.e. mechanical properties of the artery (44) are displayed on the displaying device (16).

Abstract: In a process of varying pressure of a pressure container (24) accommodating a forearm (22) of a subject (20) in a pressure range including negative pressure, a diameter (cross-sectional shape value) (D) of an artery 44 in the forearm (22) accommodated in the pressure container (24) is measured non-invasively by a vascular diameter calculating unit (76). In addition, a display controller (display controlling means) (80) operates to display on a displaying device (16) a variation of an internal pressure (Pc) in the pressure container (24) and a variation of the diameter (D) of the artery (44) varying depending thereon. Based on the diameter (D) of the artery (44) obtained in the high pressure region, the variation of the internal pressure Pc in the pressure container 24 and the variation of the diameter (D) of the artery 44 varying depending thereon i.e. mechanical properties of the artery (44) are displayed on the displaying device (16).

Abstract: The invention provides a novel erythropoietin product prepared from the urine of healthy human but exhibiting no inhibitory effect against erythropoiesis as is the most disadvantageous problem in the product prepared from the urine of healthy human. The method for the preparation of such a product comprises adsorbing the crude erythropoietin product obtained from the urine of healthy human on to a weakly basic anion exchanger from a neutral or weakly acidic aqueous solution containing 0.1 to 0.2 mole per liter of an inorganic neutral salt such as sodium chloride and then eluting the thus adsorbed ingredients with an aqueous eluant solution containing from 0.5 to 0.7 mole per liter of an inorganic neutral salt.

Abstract: The invention provides a novel process for the production of erythropoietin, which is a promising medicine for curing anemia, from human urine containing the same. The inventive method comprises adjusting the pH value of the urine in the range from 6 to 8, if the pH value of the urine is out of this range, and contacting the thus pH-controlled urine with a specific adsorbent so as that the erythropoietin is selectively adsorbed on the adsorbent. The adsorbed erythropoietin is then eluted out by use of an eluant solution to give the product in a partially purified form.

Abstract: Method for the isolation of urokinase from human urine in which the urokinase is adsorbed and thereafter eluted with aqueous cation surfactant mixture. Novel carboxyalkyl cellulose is utilized as a preferred adsorbent.

Abstract: The activity of urokinase in aqueous solution is stabilized and enhanced by addition of water soluble amines selected from the group consisting of amino sugars, amino acids and cationic surfactants.